The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Gene Review

SCLC1  -  small cell cancer of the lung

Homo sapiens

Synonyms: SCCL, SCLC
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of SCLC1

  • A novel sequence (R659Q) was discovered near the ATP binding site in a human small cell lung cancer (SCLC) cell line, H1436 [1].
  • Furthermore, c-myc is expressed in increased amounts in some human tumour lines, and in some cases, human small cell lung cancers (SCLC) contain DMs and HSRs [2].
  • In contrast, expression of N-myc has been found only in a restricted set of tumours, most of which show neural characteristics; these include human neuroblastoma, retinoblastoma and small cell lung carcinoma (SCLC) [3].
  • Rb messenger RNA expression was absent in 60% of the SCLC lines and 75% of pulmonary carcinoid lines, including all samples with DNA abnormalities [4].
  • The finding of abnormalities of the Rb gene in SCLC and pulmonary carcinoids (both neuroendocrine tumors) suggests that this gene may be involved in the pathogenesis of a common adult malignancy [4].

Psychiatry related information on SCLC1

  • Cannibalistic cells appeared to be of SCCL origin. "Cannibalism" is never observed in serum-free cultures but can be reinduced by serum exposure [5].
  • We therefore conclude that 3-dimensional gel-histoculture is a useful means of distinguishing pure SCLC from NSCLC, which may improve treatment decision making [6].
  • CONCLUSION: The findings of this study suggest that smoking cessation results in the greatest reductions for SCLC and SQC [7].
  • A previous study had shown SCLC patients to have deficits in memory, frontal lobe executive functioning, and motor skills before they received prophylactic cranial irradiation (PCI) [8].
  • Since donepezil and vitamin E have been somewhat successful in treating other dementias, this study tested the hypothesis that these agents can prevent cognitive decline in SCLC patients [9].

High impact information on SCLC1

  • Transcript A was missing in all SCLC cell lines analysed and in several other cancer cell lines [10].
  • We reveal a similar pattern of Hh signalling in airway development during normal differentiation of pulmonary neuroendocrine precursor cells, and in a subset of small-cell lung cancer (SCLC), a highly aggressive and frequently lethal human tumour with primitive neuroendocrine features [11].
  • Adhesion of SCLC cells to ECM enhances tumorigenicity and confers resistance to chemotherapeutic agents as a result of beta1 integrin-stimulated tyrosine kinase activation suppressing chemotherapy-induced apoptosis [12].
  • Strategies based on blocking beta1 integrin-mediated survival signals may represent a new therapeutic approach to improve the response to chemotherapy in SCLC [12].
  • Because neoplastic characteristics such as decreased strand stability9 and ras mutations have been found in the plasma DNA of cancer patients, we looked for microsatellite alterations in the plasma of SCLC patients [13].

Chemical compound and disease context of SCLC1


Biological context of SCLC1

  • Our data show loss of alleles of chromosome 3p markers in tumour DNA of all nine patients supporting the hypothesis that this region contributes to tumorigenesis in SCLC [19].
  • Here we describe a third myc-related gene (L-myc) cloned from SCLC DNA with homology to a small region of both the c-myc and N-myc genes [20].
  • A cytogenetic deletion in chromosome 3 (p14-p23) was reported in small-cell lung cancer (SCLC) by Whang-Peng et al [19].
  • We used polymorphic DNA probes for chromosome 3p and compared tumour and constitutional genotypes of nine SCLC patients [19].
  • Using a molecular-genetic approach, we here present evidence for a consistent deletion at the chromosomal region 3p21, not only in SCLC, but in all major types of lung cancer [21].

Anatomical context of SCLC1


Associations of SCLC1 with chemical compounds

  • These results suggest that warfarin may be useful in the treatment of SCCL and also support the hypothesis that the blood coagulation mechanism may be involved in the growth and spread of cancer in man [14].
  • Patients with extensive stage SCLC were randomly treated with standard-dose (n = 46) or high-dose etoposide plus cisplatin (n = 44); poor-risk patients with extensive stage disease (n = 25) were assigned to standard dose etoposide plus cisplatin [26].
  • RESULTS: Sensitivities to doxorubicin and etoposide were higher in SCLC cell lines than in NSCLC lines, and the difference was statistically significant [27].
  • Before 1986, patients with limited stage SCLC were treated with a cyclophosphamide-based regimen with (n = 47) or without (n = 46) chest radiotherapy [26].
  • To determine whether drug intensification improves survival of patients with extensive SCLC, we compared this treatment with a four-drug regimen containing EP plus cyclophosphamide and 4'-epidoxorubicin (PCDE) [16].

Other interactions of SCLC1

  • Full length MRP4 cDNA was obtained from SCLC1 and SR-2 [28].
  • Both UMC-SCLC-1 and UMC-SCLC-1A demonstrated the deletion of chromosome 3p, amplification and abundant expression of N-myc, and increased expression of c-raf [29].

Analytical, diagnostic and therapeutic context of SCLC1


  1. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Chen, H.L., Gabrilovich, D., Tampé, R., Girgis, K.R., Nadaf, S., Carbone, D.P. Nat. Genet. (1996) [Pubmed]
  2. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Little, C.D., Nau, M.M., Carney, D.N., Gazdar, A.F., Minna, J.D. Nature (1983) [Pubmed]
  3. Differential expression of myc family genes during murine development. Zimmerman, K.A., Yancopoulos, G.D., Collum, R.G., Smith, R.K., Kohl, N.E., Denis, K.A., Nau, M.M., Witte, O.N., Toran-Allerand, D., Gee, C.E. Nature (1986) [Pubmed]
  4. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Harbour, J.W., Lai, S.L., Whang-Peng, J., Gazdar, A.F., Minna, J.D., Kaye, F.J. Science (1988) [Pubmed]
  5. Serum-dependent "cannibalism" and autodestruction in cultures of human small cell carcinoma of the lung. Brouwer, M., de Ley, L., Feltkamp, C.A., Elema, J., Jongsma, A.P. Cancer Res. (1984) [Pubmed]
  6. The distinction of small cell and non-small cell lung cancer by growth in native-state histoculture. Vescio, R.A., Connors, K.M., Bordin, G.M., Robb, J.A., Youngkin, T., Umbreit, J.N., Hoffman, R.M. Cancer Res. (1990) [Pubmed]
  7. Effect of smoking cessation on major histologic types of lung cancer. Khuder, S.A., Mutgi, A.B. Chest (2001) [Pubmed]
  8. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Meyers, C.A., Byrne, K.S., Komaki, R. Lung Cancer (1995) [Pubmed]
  9. Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs. Jatoi, A., Kahanic, S.P., Frytak, S., Schaefer, P., Foote, R.L., Sloan, J., Petersen, R.C. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. (2005) [Pubmed]
  10. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Dammann, R., Li, C., Yoon, J.H., Chin, P.L., Bates, S., Pfeifer, G.P. Nat. Genet. (2000) [Pubmed]
  11. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Watkins, D.N., Berman, D.M., Burkholder, S.G., Wang, B., Beachy, P.A., Baylin, S.B. Nature (2003) [Pubmed]
  12. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Sethi, T., Rintoul, R.C., Moore, S.M., MacKinnon, A.C., Salter, D., Choo, C., Chilvers, E.R., Dransfield, I., Donnelly, S.C., Strieter, R., Haslett, C. Nat. Med. (1999) [Pubmed]
  13. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Chen, X.Q., Stroun, M., Magnenat, J.L., Nicod, L.P., Kurt, A.M., Lyautey, J., Lederrey, C., Anker, P. Nat. Med. (1996) [Pubmed]
  14. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. Zacharski, L.R., Henderson, W.G., Rickles, F.R., Forman, W.B., Cornell, C.J., Forcier, R.J., Edwards, R., Headley, E., Kim, S.H., O'Donnell, J.R., O'Dell, R., Tornyos, K., Kwaan, H.C. JAMA (1981) [Pubmed]
  15. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Vincent, A., Lang, B., Newsom-Davis, J. Trends Neurosci. (1989) [Pubmed]
  16. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. Pujol, J.L., Daurès, J.P., Rivière, A., Quoix, E., Westeel, V., Quantin, X., Breton, J.L., Lemarié, E., Poudenx, M., Milleron, B., Moro, D., Debieuvre, D., Le Chevalier, T. J. Natl. Cancer Inst. (2001) [Pubmed]
  17. Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate. Curt, G.A., Jolivet, J., Carney, D.N., Bailey, B.D., Drake, J.C., Clendeninn, N.J., Chabner, B.A. J. Clin. Invest. (1985) [Pubmed]
  18. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. Ravi, R.K., Weber, E., McMahon, M., Williams, J.R., Baylin, S., Mal, A., Harter, M.L., Dillehay, L.E., Claudio, P.P., Giordano, A., Nelkin, B.D., Mabry, M. J. Clin. Invest. (1998) [Pubmed]
  19. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Naylor, S.L., Johnson, B.E., Minna, J.D., Sakaguchi, A.Y. Nature (1987) [Pubmed]
  20. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nau, M.M., Brooks, B.J., Battey, J., Sausville, E., Gazdar, A.F., Kirsch, I.R., McBride, O.W., Bertness, V., Hollis, G.F., Minna, J.D. Nature (1985) [Pubmed]
  21. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Kok, K., Osinga, J., Carritt, B., Davis, M.B., van der Hout, A.H., van der Veen, A.Y., Landsvater, R.M., de Leij, L.F., Berendsen, H.H., Postmus, P.E. Nature (1987) [Pubmed]
  22. Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin. Roy, D.C., Ouellet, S., Le Houillier, C., Ariniello, P.D., Perreault, C., Lambert, J.M. J. Natl. Cancer Inst. (1996) [Pubmed]
  23. Monoclonal antibodies reactive with small cell carcinoma of the lung. Ball, E.D., Graziano, R.F., Pettengill, O.S., Sorenson, G.D., Fanger, M.W. J. Natl. Cancer Inst. (1984) [Pubmed]
  24. CD10/NEP in non-small cell lung carcinomas. Relationship to cellular proliferation. Ganju, R.K., Sunday, M., Tsarwhas, D.G., Card, A., Shipp, M.A. J. Clin. Invest. (1994) [Pubmed]
  25. Cholera toxin inhibits signal transduction by several mitogens and the in vitro growth of human small-cell lung cancer. Viallet, J., Sharoni, Y., Frucht, H., Jensen, R.T., Minna, J.D., Sausville, E.A. J. Clin. Invest. (1990) [Pubmed]
  26. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. Georgiadis, M.S., Steinberg, S.M., Hankins, L.A., Ihde, D.C., Johnson, B.E. J. Natl. Cancer Inst. (1995) [Pubmed]
  27. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. Kasahara, K., Fujiwara, Y., Sugimoto, Y., Nishio, K., Tamura, T., Matsuda, T., Saijo, N. J. Natl. Cancer Inst. (1992) [Pubmed]
  28. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. Savaraj, N., Wu, C., Wangpaichitr, M., Kuo, M.T., Lampidis, T., Robles, C., Furst, A.J., Feun, L. Int. J. Oncol. (2003) [Pubmed]
  29. Small cell lung cancer cell line derived from a primary tumor with a characteristic deletion of 3p. Graziano, S.L., Cowan, B.Y., Carney, D.N., Bryke, C.R., Mitter, N.S., Johnson, B.E., Mark, G.E., Planas, A.T., Catino, J.J., Comis, R.L. Cancer Res. (1987) [Pubmed]
  30. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Cuttitta, F., Carney, D.N., Mulshine, J., Moody, T.W., Fedorko, J., Fischler, A., Minna, J.D. Nature (1985) [Pubmed]
  31. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. Doyle, A., Martin, W.J., Funa, K., Gazdar, A., Carney, D., Martin, S.E., Linnoila, I., Cuttitta, F., Mulshine, J., Bunn, P. J. Exp. Med. (1985) [Pubmed]
  32. Expression of insulinlike growth factor (IGF) and IGF-binding protein genes in human lung tumor cell lines. Reeve, J.G., Brinkman, A., Hughes, S., Mitchell, J., Schwander, J., Bleehen, N.M. J. Natl. Cancer Inst. (1992) [Pubmed]
WikiGenes - Universities